Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
- Published In:
- Drug design, development and therapy, 11, 2325-2331 (2017)
- Authors:
- Graf, Solomon A, Garcia, Jose M(2)
- Database ID:
- RPEP-03299
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03299APA
Graf, Solomon A; Garcia, Jose M. (2017). Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.. Drug design, development and therapy, 11, 2325-2331. https://doi.org/10.2147/DDDT.S110131
MLA
Graf, Solomon A, et al. "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.." Drug design, 2017. https://doi.org/10.2147/DDDT.S110131
RethinkPeptides
RethinkPeptides Research Database. "Anamorelin hydrochloride in the treatment of cancer anorexia..." RPEP-03299. Retrieved from https://rethinkpeptides.com/research/graf-2017-anamorelin-hydrochloride-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.